EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) [Yahoo! Finance]
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) was upgraded by analysts at StockNews.com to a "sell" rating.